NASDAQ:CRNX

Crinetics Pharmaceuticals Q2 2026 Earnings Results & Report

Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 3, 2026. The company reported EPS of -$1.14 versus the -$1.18 consensus estimate, while revenue of $25.12 million topped the $14.84 million estimate by $10.28 million. Revenue increased 2,336.9% year over year.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Crinetics Pharmaceuticals EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.18
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$1.23
EPS Beat Rate
3 of last 8 quarters

Crinetics Pharmaceuticals Revenue Results

Actual Revenue
$25.12 million
Expected Revenue
$14.84 million
Beat/Miss
Beat by +$10.28 million
YoY Revenue Growth
+2,336.90%

Crinetics Pharmaceuticals Q2 2026 Earnings FAQ

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported earnings of -$1.14 per share for Q2 2026, beating the consensus estimate of -$1.18. The report was announced on Monday, August 3, 2026.

Crinetics Pharmaceuticals reported revenue of $25.12 million for Q2 2026, against a consensus estimate of $14.84 million.

Crinetics Pharmaceuticals Earnings Headlines

Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
See More Crinetics Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crinetics Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crinetics Pharmaceuticals and other key companies, straight to your email.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies.

Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease.

Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.

View Crinetics Pharmaceuticals Profile